ES2193136T3 - Variantes de inmunoglubina para receptores especificos de fc epsilon. - Google Patents

Variantes de inmunoglubina para receptores especificos de fc epsilon.

Info

Publication number
ES2193136T3
ES2193136T3 ES92918713T ES92918713T ES2193136T3 ES 2193136 T3 ES2193136 T3 ES 2193136T3 ES 92918713 T ES92918713 T ES 92918713T ES 92918713 T ES92918713 T ES 92918713T ES 2193136 T3 ES2193136 T3 ES 2193136T3
Authority
ES
Spain
Prior art keywords
ige
receptor
immunoglubine
epsilon
variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92918713T
Other languages
English (en)
Inventor
Paula M Jardieu
Leonard G Presta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27114350&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2193136(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2193136T3 publication Critical patent/ES2193136T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE DESCRIBEN DOS CLASES DE POLIPEPTIDOS DERIVADOS DE LA IGE HUMANA. UNA CLASE SE UNE SELECTIVAMENTE AL RECEPTOR DE LA IGE DE ALTA AFINIDAD SOBRE LAS CELULAS DE BASTON Y BASOFILOS, PERO NO AL RECEPTOR DE LA IGE DE BAJA AFINIDAD SOBRE LAS CELULAS B, MONOCITOS, EOSINOFILOS Y PLAQUETAS. LA OTRA CLASE SE UNE AL RECEPTOR DE BAJA AFINIDAD, PERO NO AL RECEPTOR DE ALTA AFINIDAD. LOS POLIPEPTIDOS DE UNION DIFERENCIAL DE ESTA INVENCION SON UTILES EN PROCEDIMIENTOS DE DIAGNOSTICO PARA RECEPTORES DE LA IGE O EN LA TERAPIA DE DESORDENES INTERMEDIADOS POR LA IGE TALES COMO LAS ALERGIAS. TAMBIEN SON UTILES EN LA PREPARACION DE ANTICUERPOS CAPACES DE UNIRSE A REGIONES DE LA IGE QUE PARTICIPAN EN LA UNION DEL RECEPTOR.
ES92918713T 1991-08-14 1992-08-14 Variantes de inmunoglubina para receptores especificos de fc epsilon. Expired - Lifetime ES2193136T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74476891A 1991-08-14 1991-08-14
US87949592A 1992-05-07 1992-05-07

Publications (1)

Publication Number Publication Date
ES2193136T3 true ES2193136T3 (es) 2003-11-01

Family

ID=27114350

Family Applications (2)

Application Number Title Priority Date Filing Date
ES92918713T Expired - Lifetime ES2193136T3 (es) 1991-08-14 1992-08-14 Variantes de inmunoglubina para receptores especificos de fc epsilon.
ES02009009T Expired - Lifetime ES2296839T3 (es) 1991-08-14 1992-08-14 Variantes de inmunoglobulinas para receptores fc-epsilon especificos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES02009009T Expired - Lifetime ES2296839T3 (es) 1991-08-14 1992-08-14 Variantes de inmunoglobulinas para receptores fc-epsilon especificos.

Country Status (11)

Country Link
EP (2) EP0602126B1 (es)
JP (1) JP3457962B2 (es)
AT (1) ATE233813T1 (es)
AU (2) AU2498192A (es)
CA (1) CA2113813C (es)
DE (3) DE69233716T2 (es)
DK (2) DK0602126T3 (es)
ES (2) ES2193136T3 (es)
LU (1) LU91219I2 (es)
NL (1) NL300220I2 (es)
WO (1) WO1993004173A1 (es)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770396A (en) * 1992-04-16 1998-06-23 The United States Of America As Represented By The Department Of Health And Human Services Isolation characterization, and use of the human beta subunit of the high affinity receptor for immunoglobulin E
PT589840E (pt) * 1992-09-24 2004-08-31 Tanox Biosystems Inc Anticorpos monoclonais reformulados contra um isotipo de imunoglobulina
US5958708A (en) * 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US6066718A (en) * 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5928904A (en) * 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US20020193575A1 (en) 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
GB9324013D0 (en) * 1993-11-22 1994-01-12 3I Res Expl Ltd Polypeptides
EP0739214B1 (en) * 1994-01-18 1998-03-18 Genentech, Inc. A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US20040197326A1 (en) * 1995-07-27 2004-10-07 Genentech, Inc. Method for treatment of allergic asthma
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP0885244B2 (en) * 1996-03-01 2008-04-16 Novartis AG Peptide immunogens for vaccination against and treatment of allergy
US5958880A (en) * 1996-12-19 1999-09-28 Heska Corporation Feline Fc epsilon receptor alpha chain proteins and therapeutic uses thereof
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6057127A (en) * 1998-01-29 2000-05-02 Heska Corporation Equine Fc epsilon receptor alpha chain nucleic acid molecules and uses thereof
US7393529B2 (en) * 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
US6504013B1 (en) * 2000-02-01 2003-01-07 Idexx Laboratories, Inc. Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6299875B1 (en) * 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
TWI227241B (en) 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
CZ20013081A3 (cs) * 1999-02-25 2002-02-13 Smithkline Beecham Biologicals S. A. Epitopy a mimotopy získané z oblastí C-epsilon-2 nebo C-epsilon-4 IgE, jejich antagonisté a jejich terapeutické pouľití
US6889145B1 (en) 2000-03-15 2005-05-03 Northwestern University Three-dimensional model of a Fc region of an IgE antibody and uses thereof
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
IL155002A0 (en) 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
JP4460302B2 (ja) 2002-02-05 2010-05-12 ジェネンテック インコーポレイテッド タンパク質精製法
JP4319979B2 (ja) 2002-04-26 2009-08-26 ジェネンテック・インコーポレーテッド タンパク質の非アフィニティ精製
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1558647B1 (en) 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
DK1610820T4 (da) 2003-04-04 2013-11-04 Genentech Inc Høj-koncentration antistof- og proteinformuleringer
PL3095793T3 (pl) 2003-07-28 2020-09-07 Genentech, Inc. Redukcja wycieku białka A w trakcie chromatografii powinowactwa z białkiem A
EP1673395A1 (en) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
TWI320788B (en) 2005-05-25 2010-02-21 Hoffmann La Roche Method for the purification of antibodies
WO2007032804A2 (en) 2005-06-30 2007-03-22 Clifford Risk Novel uses for anti-ige therapy
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8163886B2 (en) 2006-12-21 2012-04-24 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
JP5361738B2 (ja) 2007-01-22 2013-12-04 ジェネンテック， インコーポレイテッド 多価電解質沈殿物及びタンパク質の精製
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
WO2009009523A2 (en) 2007-07-09 2009-01-15 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
PE20090499A1 (es) 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37
CA2697656C (en) * 2007-08-23 2017-10-03 Mitsubishi Chemical Medience Corporation Non-specific reaction inhibitor
CL2008003218A1 (es) 2007-10-30 2009-03-06 Genentech Inc Método para la purificación de un anticuerpo a partir de una composición que comprende el anticuerpo y al menos un contaminante.
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
KR101843915B1 (ko) 2008-08-14 2018-04-02 제넨테크, 인크. 고유 단백질 대체 이온 교환 막 크로마토그래피를 이용한 오염물의 제거 방법
WO2010030670A2 (en) 2008-09-10 2010-03-18 Genentech, Inc. Compositions and methods for the prevention of oxidative degradation of proteins
ES2749232T3 (es) 2008-12-16 2020-03-19 Emd Millipore Corp Reactor de tanque agitado y procedimiento
CN102256993A (zh) 2008-12-16 2011-11-23 米利波尔公司 蛋白的纯化
EP2400992B1 (en) 2009-02-27 2015-07-22 Genentech, Inc. Methods and compositions for protein labelling
CA2754528A1 (en) 2009-03-06 2010-09-10 Genetech, Inc. Antibody formulation
SI2464725T2 (sl) 2009-08-11 2025-06-30 F. Hoffmann-La Roche Ag Proizvodnja beljakovin v medijih za celične kulture brez glutamina
CA2772653C (en) 2009-09-01 2019-06-25 Genentech, Inc. Enhanced protein purification through a modified protein a elution
KR102218495B1 (ko) 2010-03-22 2021-02-19 제넨테크, 인크. 단백질-함유 제제의 안정화에 유용한 조성물 및 방법
JP2013525484A (ja) 2010-05-03 2013-06-20 ジェネンテック， インコーポレイテッド タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
SG10201804385YA (en) 2010-05-17 2018-06-28 Emd Millipore Corp Stimulus responsive polymers for the purification of biomolecules
RU2614125C2 (ru) 2010-05-28 2017-03-22 Дженентек, Инк. Снижение уровня лактата и увеличение продукции полипептида путем ингибирования экспрессии лактатдегидрогеназы и киназы пируватдегидрогеназы
MY161390A (en) 2010-06-24 2017-04-14 Genentech Inc Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
RU2013110844A (ru) 2010-08-13 2014-09-20 Дженентек, Инк. АНТИТЕЛА ПРОТИВ IL-1β И IL-18, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
KR101902225B1 (ko) 2011-07-08 2018-09-28 이엠디 밀리포어 코포레이션 일회용 생명공학적 공정용의 개선된 심층 필터
WO2013087911A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
IL267585B (en) 2011-12-22 2022-09-01 Genentech Inc Ion exchange membrane chromatography
SG11201406112TA (en) 2012-03-27 2014-10-30 Genentech Inc Improved harvest operations for recombinant proteins
MY188825A (en) 2012-05-18 2022-01-06 Genentech Inc High-concentration monoclonal antibody formulations
GB2503883A (en) * 2012-07-09 2014-01-15 King S College London Variant IgE with reduced affinity to CD23
EP2934602B1 (en) 2012-12-19 2019-02-27 Genentech, Inc. Methods and compositions for radiohalogen protein labeling
MX2017000231A (es) 2014-07-09 2017-06-27 Genentech Inc Ajuste del ph para mejorar la recuperacion por descongelamiento de bancos de celulas.
KR20190012145A (ko) 2016-03-29 2019-02-08 젤터, 인코포레이티드 주변세포질 부피 대 세포질 부피의 비가 0.5:1 내지 10:1인 그람-음성 박테리아에서의 단백질의 발현
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
AU2017382281B2 (en) 2016-12-22 2024-07-11 Genentech, Inc. Methods and formulations for reducing reconstitution time of lyophilized polypeptides
CA3049967C (en) * 2017-01-06 2024-10-01 Univ California Therapeutic anti-ige antibodies and methods and compositions thereof
WO2018224673A1 (en) 2017-06-08 2018-12-13 Zaklady Farmaceutyczne Polpharma S.A. Improved methods of cell culture
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
CA3081560A1 (en) 2017-11-07 2019-05-16 Hubit Genomix, Inc. Method for primary prevention of allergic disorders during infancy through ige-class-specific immunosuppression
CA3104684A1 (en) 2018-07-03 2020-01-09 Bristol-Myers Squibb Company Methods of producing recombinant proteins
KR20210074341A (ko) 2018-10-10 2021-06-21 베링거 인겔하임 인터내셔날 게엠베하 고밀도 생물 반응기 배양에서 막 기체 전달을 위한 방법
KR20210145152A (ko) 2019-04-01 2021-12-01 제넨테크, 인크. 단백질-함유 제제들의 안정화를 위한 조성물들 및 방법들
JP7777451B2 (ja) 2019-04-12 2025-11-28 ジェルター， インコーポレイテッド 組換えエラスチンおよびその産生
US20220315887A1 (en) 2019-08-01 2022-10-06 Bristol-Myers Squibb Company Methods of improving protein productivity in fed-batch cell cultures
AU2020358898B2 (en) * 2019-10-01 2025-10-16 Epsilogen Ltd Hybrid antibody
AU2021306786A1 (en) 2020-07-10 2023-02-16 Jiangxi Jemincare Group Co., Ltd. Anti-IgE engineered antibody and application thereof
WO2022066595A1 (en) 2020-09-22 2022-03-31 Bristol-Myers Squibb Company Methods for producing therapeutic proteins
WO2023015234A1 (en) 2021-08-05 2023-02-09 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
US20240390869A1 (en) 2021-09-21 2024-11-28 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954617A (en) * 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
JPS63225397A (ja) * 1986-10-03 1988-09-20 Dainippon Pharmaceut Co Ltd 抗アレルギー作用を有する新規ペプチド
US4940782A (en) * 1987-06-08 1990-07-10 G. D. Searle & Co. Monoclonal antibodies against IgE-associated determinants, hybrid cell lines producing these antibodies, and use therefore
GB8727045D0 (en) * 1987-11-19 1987-12-23 Research Corp Ltd Immunoglobulin e competitor
DE3853636T3 (de) * 1987-12-31 1999-04-08 Tanox Biosystems, Inc., Houston, Tex. Antigene epitope, die sich ausschliesslich auf ige-tragenden b-lymphocyten befinden.

Also Published As

Publication number Publication date
DE69232944T2 (de) 2003-12-24
DE122006000006I1 (de) 2006-04-27
DE69233716D1 (de) 2008-01-03
HK1014542A1 (en) 1999-09-30
NL300220I1 (nl) 2006-04-03
EP0602126A1 (en) 1994-06-22
DE69232944D1 (de) 2003-04-10
DE122006000006I2 (de) 2011-06-16
JP3457962B2 (ja) 2003-10-20
AU706584C (en) 2003-07-10
JPH06509944A (ja) 1994-11-10
AU7038096A (en) 1997-01-16
EP0602126B1 (en) 2003-03-05
EP1260521A2 (en) 2002-11-27
LU91219I2 (fr) 2006-04-03
EP1260521B1 (en) 2007-11-21
NL300220I2 (nl) 2006-08-01
DK0602126T3 (da) 2003-06-16
HK1050696A1 (en) 2003-07-04
CA2113813C (en) 2005-04-12
WO1993004173A1 (en) 1993-03-04
EP1260521A3 (en) 2004-01-02
ES2296839T3 (es) 2008-05-01
DE69233716T2 (de) 2008-10-30
AU2498192A (en) 1993-03-16
ATE233813T1 (de) 2003-03-15
CA2113813A1 (en) 1993-03-04
AU706584B2 (en) 1999-06-17
DK1260521T3 (da) 2008-03-25

Similar Documents

Publication Publication Date Title
ES2193136T3 (es) Variantes de inmunoglubina para receptores especificos de fc epsilon.
CA2345024A1 (en) Modified tgf-.beta. superfamily proteins
ES2150898T3 (es) Receptor humano fc(gamma)riii.
ES2187946T3 (es) Uso de interleucina-15.
IL132614A0 (en) Human toll-like receptor proteins related reagents and methods
ATE317852T1 (de) Pollen allergene
PT842273E (pt) Ligando de receptor vegf-c
IL93660A0 (en) Dna encoding the beta-chain of il-2 receptor,its preparation,host cells comprising it and monoclonal antibodies directed against it
AU8982691A (en) The use of pairs of peptides with extremely high specific affinity for one another in the area of in vitro diagnosis
PT954333E (pt) Receptores soluveis de linfotoxina-beta, anticorpos de receptores de anti-linfotoxina e anticorpos de ligandos de anti-linfotoxina como agentes terapeuticos para o tratamento de doencas imunologicas
DE69714451D1 (de) Prionbindende proteine und deren verwendungen
ES2142317T3 (es) Polipeptidos de proteinas s y uso de los mismos.
AU666482B2 (en) Human herpesvirus type 6 protein p100, the corresponding DNA sequences, their preparation and use
EP0651800A4 (en) PROTEINS ENCOUNTERED IN BASOPHILIC GRANULATIONS.